The Effects of COVID-19 on Psoriasis Patients Using Biologic Treatment: Two-Center Retrospective Study

Basit Öğe Kaydı
dc.authorscopusid57218646860
dc.authorscopusid8869567400
dc.authorscopusid24474315100
dc.authorscopusid57226856433
dc.authorscopusid57709908200
dc.authorscopusid56690015300
dc.authorscopusid16643357400
dc.contributor.authorKus, Mine Mujde
dc.contributor.authorOzturk, Perihan
dc.contributor.authorDogramaci, Asena Cigdem
dc.contributor.authorGuner, Mehmet Enes
dc.contributor.authorBozkurt, Yemliha
dc.contributor.authorNazik, Hulya
dc.contributor.authorMulayim, Mehmet Kamil
dc.date.accessioned2024-09-19T15:43:47Z
dc.date.available2024-09-19T15:43:47Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjective: The aim of our study is to evaluate the status of continuation of treatment of our patients who received biologic treatment during the pandemic and how they were affected by coronavirus disease-2019 (COVID-19). Material and Methods: The clinical processes of patients with moderate-severe plaque psoriasis who were treated with biologics between March 2020 and February 2021 were evaluated. Results: Thirty-three (21.2%) of our 156 psoriasis patients who received biologic therapy stopped treatment at the beginning of the pandemic. Fourteen of the 123 patients who were continuing the treatment were positive for COVID-19. One of the 33 psoriasis patients who stopped biologic treatment was positive for COVID-19. There was no statistical difference between those who continued with biologic treatment and those who did not in the rates of positivity for COVID- 19 after contact with a COVID-19 positive person, and frequency of severe symptoms (p=0.607, p=1.00, respectively). In terms of the difference between the mean of Psoriasis Area Severity Index (PASI) scores at the onset of the pandemic and the mean of PASI scores at the 12th month, there was no statistical difference between those who were positive for COVID-19 and those who did not (p=0.782). Conclusion: We have observed that the treatment with biologic agents in psoriasis patients does not increase the COVID-19 transmission risk, does not cause severe disease, and does not increase the hospitalization rate and mortality rate. © 2022 OrtadogŸu Reklam Tanitim Yayincilik Turizm Egitim Insaat Sanayi ve Ticaret A.S.. All rights reserved.en_US
dc.identifier.doi10.5336/dermato.2021-86216
dc.identifier.endpage28en_US
dc.identifier.issn1300-0330
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85130709018en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage22en_US
dc.identifier.trdizinid523084en_US
dc.identifier.urihttps://doi.org/10.5336/dermato.2021-86216
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/523084
dc.identifier.urihttps://hdl.handle.net/20.500.12483/14559
dc.identifier.volume32en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherOrtadogŸu Reklam Tanitim Yayincilik Turizm Egitim Insaat Sanayi ve Ticaret A.S.en_US
dc.relation.ispartofTurkiye Klinikleri Dermatolojien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectbiological therapyen_US
dc.subjectCOVID-19en_US
dc.subjectpsoriasisen_US
dc.subjectPsoriasis Area Severity Indexen_US
dc.titleThe Effects of COVID-19 on Psoriasis Patients Using Biologic Treatment: Two-Center Retrospective Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu